Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2024
Historique:
received: 20 06 2023
accepted: 30 09 2023
medline: 2 1 2024
pubmed: 2 1 2024
entrez: 2 1 2024
Statut: epublish

Résumé

Radionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [

Identifiants

DOI: 10.7150/thno.87345 PMID: 38164150 PMC: PMC10750207
pubmed: 38164150
doi: 10.7150/thno.87345
pii: thnov14p0017
pmc: PMC10750207
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-32

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Auteurs

Susan Richter (S)

Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Charlotte Steenblock (C)

Department of Internal Medicine III, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Alessa Fischer (A)

Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich, Switzerland.

Sandy Lemm (S)

Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany.

Christian G Ziegler (CG)

Department of Internal Medicine III, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
University Hospital Würzburg, Division of Endocrinology and Diabetes, Würzburg, Germany.

Nicole Bechmann (N)

Institute for Clinical Chemistry and Laboratory Medicine, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Svenja Nölting (S)

Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich (USZ), and University of Zurich (UZH), Zurich, Switzerland.
Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.

Jens Pietzsch (J)

Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.
Faculty of Chemistry and Food Chemistry, School of Science, Technische Universität Dresden, Dresden, Germany.

Martin Ullrich (M)

Department of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.

Classifications MeSH